Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

PetMed (PET) Focuses On Advertising To Boost New Order Sales

Published 02/26/2018, 09:48 PM
Updated 07/09/2023, 06:31 AM

On Feb 26, we issued an updated research report on PetMed Express, Inc. (NASDAQ:PETS) . The stock carries a Zacks Rank #1 (Strong Buy). The company is striving to implement several strategies to revitalize its top line. These include increased focus on advertising efficiency to boost new order sales and shifting sales to higher margin items, while also expanding the product line.

After several quarters of a drag in new order sales, we are impressed with PetMed’s improved performance last fiscal. The current year has demonstrated bullish momentum so far. PetMed is also working on improving the effectiveness of its campaigns. It has been quite successful in driving its sales via the Internet.

PetMed offers a wide range of products for dogs, cats and horses. We believe with the improvement in economic conditions, PetMed’s wide range of products will help drive growth in the coming quarters.

However, with an aim to increase the recognition of its brand names, PetMed markets its products through national advertising campaigns. Under this procedure, the company has been incurring huge expenses related to advertising campaigns in recent times. Hence, escalating advertising expenses exert pressure on the bottom line. Also, a tough competitive landscape is a major concern.

Stock Performance & Estimate Revision

Over the last year, PetMed has outperformed its industry. The company has gained 123.9% compared with 65.9% of the industry.

Also, the estimate revision trend for the current year is favorable with one estimate moving north over the last two months, compared with no movement in the opposite direction. Earnings estimates moved up 6.7% to $1.76.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Other Key Picks

Other top-ranked stocks in the broader medical sector are PerkinElmer (NYSE:PKI) , Bio-Rad Laboratories (NYSE:BIO) and Becton, Dickinson and Company (NYSE:BDX) .

Bio-Rad Laboratories has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 25%.

PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2.

Becton, Dickinson and Company is a Zacks #2 Ranked player. The company has a long-term expected earnings growth rate of 13.3%.

Zacks Top 10 Stocks for 2018

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?

Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp (NYSE:FMC). and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2018 today >>



PetMed Express, Inc. (PETS): Free Stock Analysis Report

PerkinElmer, Inc. (PKI): Free Stock Analysis Report

Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report

Becton, Dickinson and Company (BDX): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.